Purpose: Resectable oral tongue squamous cell carcinoma has little evidence on treatment results (OTSCC). In this investigation, treatment outcomes for resectable OTSCC were evaluated, failure patterns were investigated, and potential clinicopathological prognostic variables influencing treatment outcomes were identified. Materials and Methods: It is a retrospective review of 202 patients with resectable OTSCC who underwent main upfront surgery, adjuvant radiation, and concomitant chemotherapy as needed. Results: The average follow-up period was 35.2 months (range, 1.2 to 99.9 months). Locoregional control (LRC) lasted an average of 84.9 months (95% confidence interval: 67.3-102.4). The LRC rate across three and five years was 68.5% and 58.3%, respectively. Increased pT stage, increased pN stage, and the presence of extracapsular extension (ECE) were substantially linked with worse LRC, according to multivariate analysis. At the time of study, the median overall survival time (OS) had not been attained. The 3- and 5-year OS rates were, respectively, 70.5% and 66.6%. Increasing pT stage and the presence of ECE were strongly related with a worse OS, according to multivariate analyses. Conclusion: In resectable OTSCC, locoregional failure continues to be the primary factor in treatment failure. Given the low LRC and OS, there is potential to significantly improve the prognosis. Strong prognostic variables include the pathological T-stage, N-stage, and ECE. To confirm whether adjuvant therapy improves treatment outcomes in instances with lymphovascular invasion, depth of invasion and perineural invasion and to assist doctors in customising adjuvant therapy, more study is needed.

Purpose: Resectable oral tongue squamous cell carcinoma has little evidence on treatment results (OTSCC). In this investigation, treatment outcomes for resectable OTSCC were evaluated, failure patterns were investigated, and potential clinicopathological prognostic variables influencing treatment outcomes were identified. Materials and Methods: It is a retrospective review of 202 patients with resectable OTSCC who underwent main upfront surgery, adjuvant radiation, and concomitant chemotherapy as needed. Results: The average follow-up period was 35.2 months (range, 1.2 to 99.9 months). Locoregional control (LRC) lasted an average of 84.9 months (95% confidence interval: 67.3-102.4). The LRC rate across three and five years was 68.5% and 58.3%, respectively. Increased pT stage, increased pN stage, and the presence of extracapsular extension (ECE) were substantially linked with worse LRC, according to multivariate analysis. At the time of study, the median overall survival time (OS) had not been attained. The 3- and 5-year OS rates were, respectively, 70.5% and 66.6%. Increasing pT stage and the presence of ECE were strongly related with a worse OS, according to multivariate analyses. Conclusion: In resectable OTSCC, locoregional failure continues to be the primary factor in treatment failure. Given the low LRC and OS, there is potential to significantly improve the prognosis. Strong prognostic variables include the pathological T-stage, N-stage, and ECE. To confirm whether adjuvant therapy improves treatment outcomes in instances with lymphovascular invasion, depth of invasion and perineural invasion and to assist doctors in customising adjuvant therapy, more study is needed.